Active Filter(s):
Details:
SteroTherapeutics will provide the study drug (non-androgenic analogue of dehydroepiandrosterone) and placebo to enable the NICHD to conduct the Phase 2 clinical trial in the treatment of the manifestations of Cushing syndrome.
Lead Product(s): Fluasterone
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 02, 2020